Explore the vast range of titles available.

Potassium-ion batteries (KIBs) are promising electrochemical energy storage systems because of their low cost and high energy density. However, practical exploitation of KIBs is hampered by the lack of high-performance cathode materials. Here we report a potassium manganese hexacyanoferrate (K 2 Mn[Fe(CN) 6 ]) material, with a negligible content of defects and water, for efficient high-voltage K-ion storage. When tested in combination with a K metal anode, the K 2 Mn[Fe(CN) 6 ]-based electrode enables a cell specific energy of 609.7 Wh kg −1 and 80% capacity retention after 7800 cycles. Moreover, a K-ion full-cell consisting of graphite and K 2 Mn[Fe(CN) 6 ] as anode and cathode active materials, respectively, demonstrates a specific energy of 331.5 Wh kg −1 , remarkable rate capability, and negligible capacity decay for 300 cycles. The remarkable electrochemical energy storage performances of the K 2 Mn[Fe(CN) 6 ] material are attributed to its stable frameworks that benefit from the defect-free structure. Potassium-ion battery is a promising candidate for post-Li-ion energy storage but the lack of cathode materials hinders practical exploitation. Here the authors investigate defect-free potassium manganese hexacyanoferrate as cathode active material for high energy and long lifespan K-based cells.

Patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) are typically placed in a laminar air flow room until hematopoietic reconstitution occurs. In this study, we compared the differences in clinical outcomes between patients receiving allo-HSCT in a conventional laminar flow room (n = 200) and those receiving allo-HSCT in a plasma sterilizer environment (n = 201). The overall infection rates (20.4% vs 25.5%, P = 0.224) and the sites of infection (sepsis, perianal infection, and catheter-related infection) were comparable between the two groups. Additionally, the engraftment times were comparable between the two groups in terms of time to allo-HSCT, leukocyte engraftment time, and platelet engraftment time. The 100-day posttransplantation clinical outcomes were also comparable between the two groups in terms of the probability of overall survival (98.5% vs 99.5%, P = 0.316), leukemia-free survival (96.5% vs 96.5%, P = 0.991), the cumulative incidence of relapse (2.0% vs 3.0%, P = 0.523), non-relapse mortality (1.5% vs 0.5%, P = 0.316) and acute graft-versus-host disease (23.4% vs 22.0%, P = 0.723). Thus, our results demonstrated that receiving allo-HSCT via a plasma sterilizer did not increase the risk of pre-engraftment infection, and the clinical outcomes of these patients were comparable to those of patients in a conventional laminar flow room. Graphical Abstract

Psoriasis is a severe disease associated with the disturbance of metabolism and inflammation, but the molecular mechanisms underlying these aspects of psoriasis pathology are poorly understood. Here, we report that glutaminase 1-mediated (GLS1-mediated) glutaminolysis was aberrantly activated in patients with psoriasis and in psoriasis-like mouse models, which promoted Th17 and γδ T17 (IL-17A-producing γδ T) cell differentiation through enhancement of histone H3 acetylation of the Il17a promoter, thereby contributing to the immune imbalance and development of psoriasis. We further demonstrate that mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease was constitutively active in psoriatic CD4+ and γδ T cells, thereby supporting GLS1 expression by stabilizing c-Jun, which directly binds to the GLS1 promoter region. Blocking the activity of either GLS1 or MALT1 protease resolved Th17 and γδ T17 cell differentiation and epidermal hyperplasia in the psoriasis-like mouse models. Finally, IL-17A enhanced GLS1 expression via the MALT1/cJun pathway in keratinocytes, resulting in hyperproliferation of and chemokine production by keratinocytes. Our findings identify the role of the MALT1/cJun/GLS1/glutaminolysis/H3 acetylation/T17 axis in psoriasis pathogenesis and reveal potential therapeutic targets for this disease.

Background: Macrofocal multiple myeloma (MFMM) is characterized by clonal plasma cells comprising less than 20% of the bone marrow, multiple lytic bone lesions, and the absence of anemia, renal insufficiency, and hypercalcemia. This subtype of multiple myeloma (MM) has a relatively low incidence. Prognostic staging and cytogenetic guidance for MFMM are often insufficient due to the low tumor burden in the bone marrow. Large cohort studies on this subgroup during the era of novel agents are limited. Objectives: We aim to describe the clinical characteristics and prognostic markers of MFMM patients undergoing treatment with novel agents. Methods: Consecutive cases of MM patients diagnosed at Peking University People’s Hospital and Fu Xing Hospital of Capital Medical University from 2011 to 2023 were screened. A propensity score matching was conducted with a 2:1 ratio, matching classic MM patients to MFMM patients based on clinical variables of age and year of diagnosis. Results: We identified 91 cases (4%) of MFMM and 182 matched classic MM among 2291 MM patients. The MFMM cohort had a higher proportion of male patients, those with <90% clonal plasma cells in the bone marrow by multiparameter flow cytometry, and patients with extramedullary disease, along with a lower proportion of patients with high-risk cytogenetics or advanced disease staging. MFMM patients demonstrated better overall responses compared to the control cohort (p = 0.027) in those not receiving upfront autologous stem cell transplantation (ASCT). During a median follow-up of 42.8 months for the entire cohort, the MFMM cohort exhibited significantly superior progression-free survival (PFS) and overall survival (OS) compared to the control cohort. In multivariate analysis of the entire cohort, exposure to immunomodulatory drugs and ASCT consolidation in frontline therapy were independently associated with improved PFS and OS. For the MFMM cohort, a Ki-67 index ⩾20% was associated with inferior PFS, providing valuable prognostic information in a group where staging and cytogenetic guidance are often inadequate. Conclusion: We concluded that treatment strategies for MFMM patients should align with those for standard MM, and a Ki-67 index ⩾20% in biopsy samples of plasmacytoma is associated with inferior PFS. Plain language summary Understanding macrofocal multiple myeloma in novel agent era Macrofocal multiple myeloma (MFMM) is a rare form of multiple myeloma. Our study found that MFMM patients had better outcomes with new treatments compared to typical cases. A high Ki-67 index was linked to worse outcomes, highlighting its importance in prognosis. We also emphasized that treatment strategies for MFMM patients should align with those for standard MM.

Background This study compares the efficacy and safety of single autologous stem cell transplantation (ASCT) versus tandem ASCT for multiple myeloma (MM) patients in the era of novel agents. Methods A total of 112 high‐risk MM patients were included (single ASCT, (n = 57) or tandem ASCT(n = 55) in this retrospective multicenter study. Responses and outcomes were evaluated. Results At 100 days after ASCT1 and ASCT2, 36 (63.2%) versus 45 (81.8%) patients achieved sCR/CR, 16 (28.1%) versus 7 (12.7%) patients achieved VGPR, and 5 (8.8%) versus 1 (1.8%) patient achieved PR, respectively, in the single and tandem ASCT cohorts. The 3‐year cumulative incidence of non‐relapse mortality and disease progression was 0% versus 7.3% (p = 0.083), and 45.8% versus 25.8% (p = 0.039), respectively, for the single and tandem ASCT cohort. The tandem ASCT cohort showed a trend of better 3‐year probability of PFS (58.1% vs. 64.7%, p = 0.064) compared with the single ASCT cohort. In multivariate analysis, ultra high‐risk and achieving

Journal Article

Share this book

Add to My Shelf